Article Text

PDF
FRI0050 Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases
  1. S. Rollefstad1,
  2. E. Ikdahl1,
  3. J. Hisdal2,
  4. I.C. Olsen3,
  5. K.T. Smerud4,
  6. G. Kitas5,
  7. T.R. Pedersen6,
  8. T.K. Kvien3,7,
  9. A.G.P. Semb1
  1. 1Preventive Cardio-Rheuma clinic, Diakonhjemmet Hospital
  2. 2Section of Vascular Investigations, Oslo University Hospital Aker
  3. 3Rheumatology, Diakonhjemmet Hospital
  4. 4Smerud Medical Research International AS, Oslo, Norway
  5. 5Dudley Group NHS Foundation Trust, West Midlands, United Kingdom
  6. 6Centre of Preventive Medicine, Oslo University Hospital Ulleval
  7. 7Faculty of Medicine, University of Oslo, Oslo, Norway

Abstract

Background Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndrome. Statin treatment with low density lipoprotein cholesterol (LDL-c) goal ≤1.8 mmol/L is recommended for the general population in patients with CP.

Objectives Our objective was to evaluate the effect of 18 months intensive statin treatment on CP height in patients with inflammatory joint disease (IJD).

Methods Patients with CP and IJD [RA (n=55), ankylosing spondylitis (n=21) and psoriatic arthritis (n=10)] were treated with rosuvastatin to obtain LDL-c goal. CP height was evaluated by B–mode ultrasound.

Results The mean age was 60.8±8.5 (mean ± SD) and the gender distribution was 52 (60.5%)/34 (39.5%) [female/male]. Compliance of rosuvastatin usage was 97.9 (96.0, 99.4)[median (IQR)]. At baseline, the median number of CP was 1.0 (1-6) (range), with a median height of 1.80 mm (1.60, 2,10) (IQR). Change in CP height after 18 months on rosuvastatin treatment (mean dose 30.7±14.7 mg) was -0.20±0.34 mm (one-sample t-test, p<0.001). Baseline LDL-c was 4.0±0.9 mmol/L and the change in LDL-c was mmol/L -2.3±0.8 mmol/L (one-sample t-test, p<0.001). Mean LDL-c level during 18 months rosuvastatin treatment was 1.7±0.4 mmol/L. Fifty-three patients (61.6%) achieved LDL-c goal. In a linear regression model (age/gender adjusted) the degree of CP height reduction was independent of the LDL-c level exposure during the study period (p=0.36). Attainment of LDL-c ≤1.8 mmol/L or the change in LDL-c level did not influence degree of CP height reduction (p=0.44 and p=0.46, respectively). In a logistic regression model age, gender, blood pressure and use of biologic medication did not contribute to the CP height reduction.

Conclusions Intensive lipid lowering with rosuvastatin induced regression of CP height and reduced LDL-c significantly in patients with IJD. The LDL-c goal attainment, the change in LDL-c or the LDL-c level exposure during the study period did not influence the degree of CP height reduction.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3675

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.